Genocea Biosciences, Inc.

Equities

GNCAQ

US3724274010

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 15:56:51 10/05/2024 BST			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	0.00%

2023	Genocea Biosciences, Inc. Went Out of Business	CI
2023	Liquidation Plan Approved for Genocea Biosciences, Inc.	CI

Genocea Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021

April 29, 2021 at 12:13 pm

Genocea Biosciences, Inc. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced operating loss was USD 12.422 million compared to USD 13.375 million a year ago. Net loss was USD 11.983 million compared to USD 12.853 million a year ago. Basic loss per share from continuing operations was USD 0.18 compared to USD 0.46 a year ago. Diluted loss per share from continuing operations was USD 0.17 compared to USD 0.46 a year ago.

Latest news about Genocea Biosciences, Inc.

Genocea Biosciences, Inc. Went Out of Business	19/05/23	CI
Liquidation Plan Approved for Genocea Biosciences, Inc.	11/05/23	CI
First Amended Disclosure Statement Filed by Genocea Biosciences, Inc.	21/03/23	CI
Disclosure Statement Approved for Genocea Biosciences, Inc.	21/03/23	CI
Joint Liquidation Plan and DIsclosure Statement Filed by Genocea Biosciences, Inc.	09/02/23	CI
Motion for Asset Sale Approved for Genocea Biosciences, Inc.	21/09/22	CI
Motion for Asset Sale Approved for Genocea Biosciences, Inc.	17/08/22	CI
Bidding Procedure Approved for Genocea Biosciences, Inc.	09/08/22	CI
Motion for Asset Sale Filed by Genocea Biosciences, Inc.	04/08/22	CI
Genocea Biosciences, Inc. Filed for Bankruptcy	05/07/22	CI
Genocea Biosciences, Inc.(NasdaqCM:GNCA) dropped from S&P TMI Index	07/06/22	CI
Genocea Biosciences, Inc.(NasdaqCM:GNCA) dropped from NASDAQ Composite Index	02/06/22	CI
Genocea Biosciences, Inc. Announces Resignation of Ali Behbahani from Board of Director	01/06/22	CI
US Futures Move Lower Ahead of Durable Goods, Investor Confidence Reports	25/05/22	MT
Top Premarket Gainers	25/05/22	MT
Genocea Biosciences To Wind Down Operations; Shares Fall	24/05/22	MT
Genocea Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	05/05/22	CI
Top Premarket Decliners	29/04/22	MT
HC Wainwright Downgrades Genocea Biosciences to Neutral From Buy	29/04/22	MT
Stifel Downgrades Genocea Biosciences to Hold From Buy, Adjusts Price Target to $0.16 From $4.70	29/04/22	MT
Genocea Announces Plan to Explore Strategic Alternatives	28/04/22	CI
Transcript : Genocea Biosciences, Inc. Presents at AACR Annual Meeting 2022, Apr-08-2022 through Apr-14-2022	11/04/22
Baird Adjusts Price Target on Genocea Biosciences to $3 From $8, Keeps Outperform Rating	11/04/22	MT
Wall Street Set for Losses, Surging Treasury Yield Fuels Tech Slump	11/04/22	MT
Top Premarket Gainers	11/04/22	MT

Chart Genocea Biosciences, Inc.

Duration

Period

More charts

Company Profile

Genocea Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, or Inhibigens, that drive pro-tumor immune responses. Its GEN-009 is an investigational neoantigen vaccine delivering adjuvanted synthetic long peptides from ATLAS-identified neoantigens. The Company has a license agreement with Harvard College (Harvard), granting the Company a sublicensable license to one patent family, to develop, make, use, market licensed products, and perform licensed services related to the ATLAS discovery platform.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
GENOCEA BIOSCIENCES, INC.	0.00%	58
MODERNA, INC.	+42.41%	58.71B
IQVIA HOLDINGS INC.	-3.01%	41.31B
LONZA GROUP AG	+36.33%	39.2B
CELLTRION, INC.	-10.22%	27.4B
ICON PUBLIC LIMITED COMPANY	+10.46%	26.55B
ALNYLAM PHARMACEUTICALS, INC.	-22.21%	18.98B
BIO-TECHNE CORPORATION	+0.85%	12.51B
MEDPACE HOLDINGS, INC.	+26.58%	12.08B
UNITED THERAPEUTICS CORPORATION	+21.02%	11.94B

Other Biotechnology & Medical Research